Pfizer Settles $345m EpiPen Consumers Suit, But Viatris Marches On
Suit Against Viatris’ Mylan Was Set For 7 September
After “four years of vigorous litigation,” Pfizer has reached a preliminary settlement over allegations that it devised an “illegal scheme” with Viatris’ Mylan “to monopolize the market” for the EpiPen autoinjector device.
You may also be interested in...
Corporate integrity agreement requires Mylan to have an independent body review its drug classifications and US best price determinations; settlement resolves claims Mylan misclassified EpiPen to underpay rebates. Sanofi acted as whistleblower in case.
Eight years after its inception, pure-play biosimilars company Alvotech has announced plans to list on the NASDAQ via a SPAC merger that will deliver hundreds of millions in cash to fund product development and future growth.
Teva has added another major dermatology brand to its armory, with the launch of an authorized generic version of Galderma’s Epiduo Forte Gel.